Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $19.4B | $19.2B | $17.9B | $19.3B | $20.6B | $18.8B | $19.5B | $21.2B | $17.6B | $16.4B | $15.9B | $16.6B | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B |
Discover the top 50 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 50 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 50 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Bristol-Myers Squibb Company's last 12-month Revenue is $47.4B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Bristol-Myers Squibb Company's Revenue growth was 5.6%. The average annual Revenue growth rates for Bristol-Myers Squibb Company have been 3.5% over the past three years, 14.4% over the past five years.
Over the last year, Bristol-Myers Squibb Company's Revenue growth was 5.6%, which is higher than industry growth of 0.1%. It indicates that Bristol-Myers Squibb Company's Revenue growth is Good.